MSB 1.34% $1.51 mesoblast limited

Don't forget COVID and the exigency of the circumstances...

  1. 1,609 Posts.
    lightbulb Created with Sketch. 1691
    Don't forget COVID and the exigency of the circumstances surrounding the pandemic.

    I cannot see India, Brazil, etc., refusing some kind of emergency authorisation for treatment to its citizens. Or governments NOT agreeing to fund trials for COVID ARDS patients like the NIH did in the US - where all MSB had to supply was the cells. The results from the COVID ARDS trials would, I imagine, be good fodder for discussions on similar trials in other countries...with all of the results further supporting the proof of Rem-L's efficacy (particularly in conjunction with Dexamethasone) and safety. Does any of us really think that some of these countries in such dire straits would refuse to arrange similar trials to the ones funded by the NIH?

    We can make all the excuses for management that we would like...but they are clearly missing opportunities, and if they have a plan that covers more than the US, they sure haven't shared it with us...


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.